Medtech recalls Little Remedies Honey Cough Syrup due to contamination

Medtech Products, a Prestige Consumer (PBH) Healthcare company, is voluntarily recalling five lots of Little Remedies Honey Cough Syrup due to the presence of Bacillus cereus and loss of shelf-stability. The affected lots were distributed nationwide from December 14, 2022, through June 4, 2025. Bacillus cereus can cause food-borne illnesses. Consumers are advised to stop using the recalled product immediately and contact their physician if they have experienced related problems. The recall is being conducted with the knowledge of the FDA.
Confident Investing Starts Here:

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

40 minutes ago

• Medscape

Smartphone-Based Home Albuminuria Testing Boosts Screening

TOPLINE: Screening for albuminuria, a key marker of cardiorenal risk, remains inadequate among patients with diabetes or hypertension. A smartphone-enabled home testing solution, evaluated in 4000 adults, effectively increased screening rates and enabled early diagnosis of kidney disease. METHODOLOGY: Regular albuminuria testing is recommended in high-risk patients with diabetes or hypertension to enable early detection and timely intervention for kidney and cardiovascular complications; however, screening levels remains suboptimal. Researchers randomly selected 4000 adults (mean age, 61 years; 49% women; 93% White) from a large Central Pennsylvania healthcare system who had not undergone albumin-creatinine ratio testing in the previous 12 months; half the patients in the cohort had hypertension without diabetes, and the remaining half had diabetes. Patients were provided with Minuteful Kidney, an FDA-cleared, smartphone-enabled home albuminuria screening kit. Results were delivered to participants via a smartphone application and to healthcare providers through electronic health records. The intervention group was propensity score-matched with a control group receiving usual care. TAKEAWAY: Completion rates for any albumin-creatinine ratio testing were significantly higher in the intervention group than in the control group (53.1% vs 21.2%; P < .001). The impact of the intervention on albumin-creatinine ratio testing completion was more pronounced among patients with hypertension without diabetes (completion rates, 53.4% in the intervention group vs 12.5% in the control group) than among those with diabetes (completion rates, 52.7% vs 30.0%). Over 270 days of follow-up, patients tested with Minuteful Kidney had higher rates of new diagnoses of proteinuria or kidney disease (4.0% vs 2.2%; P < .001). Patients with an abnormal albumin-creatinine ratio on the home-based test demonstrated greater engagement with primary care and nephrology services and were more likely to receive prescriptions for renin-angiotensin-aldosterone system inhibitors than were those with normal results. IN PRACTICE: "A smartphone-enabled home albuminuria test is effective in increasing albuminuria screening and diagnosis of kidney disease among high-risk individuals," the authors concluded. SOURCE: The study was led by Waleed Zafar in Danville, Pennsylvania. It was presented on June 20, 2025, at the 85th Scientific Sessions – American Diabetes Association held at the McCormick Place Convention Center, Chicago. LIMITATIONS: The abstract did not discuss any limitations. DISCLOSURES: Two authors disclosed receiving research support from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Associated Press

an hour ago

• Associated Press

IBN Coverage: HeartBeam (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 20, 2025 ( NEWMEDIAWIRE ) - HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credit card-sized, cable-free device designed to deliver high-fidelity, three-directional cardiac recordings for arrhythmia evaluation. The clearance marks a major regulatory milestone and accelerates HeartBeam's plans to improve access to timely, remote cardiac care. When symptoms arise, patients use the app-guided system to record a 30-second ECG, which is automatically uploaded to the cloud for physician review in the context of medical history. The company will soon launch an Early Access Program to engage early adopters and providers ahead of broader commercialization. This foundational clearance also sets the stage for future advancements, including 12-lead ECG synthesis, AI-based arrhythmia detection, and remote heart attack risk scoring. HeartBeam's long-term vision is to revolutionize cardiac care by enabling continuous, predictive insights outside traditional clinical settings. To view the full press release, visit About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to BEAT are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected]

Yahoo

3 hours ago

• Yahoo

Little Remedies honey cough syrup recalled nationwide: What parents need to know

As parents, we do everything we can to keep our children safe—especially when they're sick. That's why a new nationwide recall of a popular over-the-counter children's cough medicine is raising serious concern. Medtech Products Inc. has voluntarily recalled several lots of Little Remedies® Honey Cough Syrup after the U.S. Food and Drug Administration (FDA) found the presence of Bacillus cereus, a harmful bacteria that can cause foodborne illness—and in severe cases, even death. The recalled syrup, a go-to for many parents looking for natural relief for their child's cough, was sold online and in stores across the U.S. between December 2022 and June 2025. While no serious injuries have been reported as of now, the company is urging families to stop using the affected products immediately. Here's what you need to know to keep your little ones safe. The recall affects Little Remedies® Honey Cough Syrup, sold in 4 FL OZ (118 mL) amber bottles, commonly found in pharmacies, grocery stores, and online retailers. The syrup is marketed as a gentle, natural remedy made with honey to soothe coughs in children — but the recent discovery of Bacillus cereus contamination has made certain lots unsafe for use. According to the official FDA notice, the bacteria was detected in certain lots, prompting a recall due to concerns about shelf stability and potential health risks. While no other Little Remedies® products are affected, all lots of this particular syrup still within the expiration date have been included in the recall out of an abundance of caution. Here are the affected lot numbers and expiration dates: Lot 0039 – Expires 11/2025 Lot 0545 – Expires 01/2026 Lot 0640 – Expires 02/2026 Lot 0450 – Expires 05/2026 Lot 1198 – Expires 12/2026 Each recalled bottle has a UPC of 7-56184-10737-9 and should have the lot number printed on both the label and the bottom of the box. If you have one of these in your medicine cabinet, read on for what steps to take next. Bacillus cereus is a type of bacteria that can cause foodborne illness when ingested — especially when it grows in products that are no longer shelf-stable. While it may sound unfamiliar to many parents, the symptoms it causes are unfortunately very recognizable. There are two common types of illness linked to B. cereus: The first appears 1 to 6 hours after exposure and typically causes nausea, vomiting, and stomach cramps. The second appears 8 to 16 hours after exposure, with symptoms including diarrhea and abdominal pain. In some cases, the diarrhea may be severe and watery. In most healthy children, these symptoms may pass on their own. However, exposure to high levels of can lead to more serious illness — and in rare cases, it can be fatal. If your child has consumed the recalled syrup and shows any of these symptoms, it's important to contact your pediatrician or seek medical attention right away. When in doubt, trust your instincts — you know your child best. Related: Here's how I'm preparing for my kids' sick days this year If you have a bottle of Little Remedies® Honey Cough Syrup at home, the first step is to stop using it immediately — even if your child has taken it without any symptoms. Check both the UPC (7-56184-10737-9) and the lot number, which can be found on the bottle label and the bottom of the box. Here's what to do next: If your child has taken the syrup and is experiencing nausea, vomiting, diarrhea, or stomach pain, call your pediatrician right away. If your child seems fine, monitor them closely for symptoms for up to 24 hours. To request a refund or report an issue, you can contact Medtech directly: Call: (800) 754-8853 (Monday–Friday, 8:30 a.m. to 5:30 p.m. ET) Email: medicalaffairs@ Website: If you or your healthcare provider believe your child experienced a reaction to the product, you can also report it through the FDA's MedWatch program at It's always okay to ask questions, trust your instincts, and reach out for guidance when your child's health is involved. Related: Target recalls baby food over lead concerns—here's what parents should do Recalls like this can feel unsettling, especially when they involve products we trust. But by staying informed and taking quick action, you're doing exactly what your child needs. No serious injuries have been reported, and the recall is precautionary — but it's always better to be safe. If you have concerns, talk to your pediatrician. When it comes to your child's health, caution is care.